featured
hs-cTnI–Guided Combination Therapy With Carvedilol and Candesartan to Prevent Anthracycline Cardiotoxicity Among Patients With Breast Cancer or Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial
Circulation 2023 Sep 25;[EPub Ahead of Print], PA Henriksen, P Hall, IR MacPherson, SS Joshi, T Singh, M Maclean, S Lewis, A Rodriguez, A Fletcher, RJ Everett, H Stavert, A Broom, L Eddie, L Primrose, H McVicars, P McKay, A Borley, C Rowntree, S Lord, G Collins, J Radford, A Guppy, MC Williams, A Japp, JR Payne, DE Newby, NL Mills, O Oikonomidou, NN LangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.